This Article Abstract Full Text (PDF) All Versions of this Article: 25/6/1186    most recent 01.ATV.0000163841.85333.83v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Genoux, A. Articles by Fruchart, J.-C. Search for Related Content PubMed PubMed Citation Articles by Genoux, A. Articles by Fruchart, J.-C. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1186.)
© 2005 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor ROR

Annelise Genoux; Hélène Dehondt; Audrey Helleboid-Chapman; Christian Duhem; Dean W. Hum; Geneviève Martin; Len A. Pennacchio; Bart Staels; Jamila Fruchart-Najib; Jean-Charles Fruchart

From Département d’Athérosclérose (A.G., H.D., A.H-C., C.D., B.S., J.F-N, J-C.F.), U.545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, Lille Cedex, France; Genfit SA (D.W.H., G.M.), Loos, France; Genomics Division (L.A.P.), Lawrence Berkeley National Laboratory, Berkeley, Calif.

Correspondence to Jamila Fruchart-Najib, U.545 INSERM, Université de Lille II, 885 avenue Eugéne Avinée, 59120 Loos, France. E-mail jfruchart{at}pharma.univ-lille2.fr

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Objective— The newly identified apolipoprotein A5 (APOA5), selectively expressed in the liver, is a crucial determinant of plasma triglyceride levels. Because elevated plasma triglyceride concentrations constitute an independent risk factor for cardiovascular diseases, it is important to understand how the expression of this gene is regulated. In the present study, we identified the retinoic acid receptor-related orphan receptor- (ROR) as a regulator of human APOA5 gene expression.

Methods and Results— Using electromobility shift assays, we first demonstrated that ROR1 and ROR4 proteins can bind specifically to a direct repeat 1 site present at the position –272/–260 in the APOA5 gene promoter. In addition, using transient cotransfection experiments in HepG2 and HuH7 cells, we demonstrated that both ROR1 and ROR4 strongly increase APOA5 promoter transcriptional activity in a dose-dependent manner. Finally, adenoviral overexpression of hROR in HepG2 cells led to enhanced hAPOA5 mRNA accumulation. We show that the homologous region in mouse apoa5 promoter is not functional. Moreover, we show that in staggerer mice, apoa5 gene is not affected by ROR.

Conclusions— These findings identify ROR1 and ROR4 as transcriptional activators of human APOA5 gene expression. These data suggest an additional important physiological role for ROR in the regulation of genes involved in lipid homeostasis and probably in the development of atherosclerosis.

Apolipoprotein A5 has recently been identified as a crucial determinant of plasma triglyceride levels. Our results showed that ROR upregulates human APOA5 but has no effect on mouse apoa5 gene. These data suggest an additional important physiological role for ROR in the regulation of genes involved in lipid homeostasis in human and probably in the development of atherosclerosis.

Key Words: apolipoprotein A5 • nuclear receptor ROR • triglyceride homeostasis • transcriptional regulation

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Cardiovascular diseases are a major cause of death in the world.^1,2 Several epidemiological studies have established that in addition to elevated low-density lipoprotein and reduced high-density lipoprotein levels, elevated blood triglyceride level is an independent risk factor for coronary heart disease.^3,4 Therefore, the identification of factors or genes capable of affecting triglyceride homeostasis is of major medical importance for the treatment of hypertriglyceridemia and associated coronary heart disease.

See page 1097

The newly identified apolipoprotein A5 (APOA5) is located proximal to the well-characterized APOA1/C3/A4 gene cluster on human 11q23. Predominantly expressed in the liver, the apolipoprotein A5 is an important determinant of plasma triglyceride levels both in humans and mice⁵ and is associated with an early phase of liver regeneration.⁶ To study the function of APOA5 on triglyceride homeostasis, human APOA5 transgenic and knockout mice were generated.⁵ Transgenic mice exhibited markedly decreased levels of plasma triglyceride that were approximately one-third of those of control mice, whereas knockout mice had 4-fold increased plasma triglycerides compared with wild-type mice. In a previous study, we investigated the mechanism by which apolipoprotein (apoA-V) affects lipid metabolism in transgenic mice overexpressing hAPOA5 gene.⁷ We found that apoA-V does not affect very-low-density lipoprotein (VLDL) triglyceride synthesis and secretion but accelerates VLDL catabolism by activating lipolysis and enhancing VLDL removal from the plasma.⁷ Taken together, these findings demonstrate that APOA5 regulates plasma triglyceride level only by increasing triglyceride catabolism in vivo. In addition, several DNA sequence polymorphisms in the gene have been found to be linked to increased plasma triglyceride levels,⁸ and subsequently to an increased risk of myocardial infarction.⁹ These data suggest that APOA5 could be a strong modulator of triglyceride levels. Therefore, studying factors that regulate its expression is of significant clinical importance for the treatment of dyslipidemia.

It was previously described that APOA5 gene expression is increased by peroxisome proliferator-activated receptor-/retinoid X receptor dimers that bind to a direct repeat 1 (DR1) sequence located at the position –272/–260 in the APOA5 gene promoter.^10,11 Recently, SREBP1c has been reported to downregulate APOA5 gene expression via a direct binding to the functional E-box present in human APOA5 promoter.¹²

The retinoic acid receptor-related orphan receptors (RORs) constitute a subfamily of orphan receptors encoded by 3 different genes, ROR, RORß, and ROR.^13–15 RORs were initially reported to bind to response elements (retinoic acid receptor-related orphan receptor response element [RORE]) consisting of a 6-bp A/T-rich sequence preceding the half-core PuGGTCA motif.^15–17 However, more complex RORE have also been described such as direct repeats of the PuGGTCA motifs preceded by a 6-bp A/T-rich sequence.¹⁸ Because of alternative splicing and promoter usage, the ROR gene gives rise to 4 isoforms: 1, 2, 3, and 4 (or RZRa),^14,15,19 which differ in their N-terminal domains and display distinct DNA recognition and transactivation properties.¹⁵ In contrast to RORß, only expressed in brain, retina, and pineal gland,²⁰ both ROR and ROR are widely expressed in peripheral tissues.^13,15,16,19 Staggerer mice (sg/sg) carry a natural deletion in the ROR gene that prevents the translation of its putative ligand-binding domain, thereby presumably disrupting the normal function of this transcription factor.²¹ Interestingly, in addition to severe neurological disorders,²² these mice display metabolic abnormalities.^23–25 These mice, maintained on an atherogenic diet, have severe hypoalphalipoproteinemia and atherosclerosis.²⁵ Furthermore, ROR has already been involved in apolipoprotein A1 and C3 gene transcriptional regulation.^23,24 These data suggest an important role for ROR in lipoprotein metabolism and cardiovascular diseases.

In the present study, we demonstrated that both ROR1 and ROR4 isoforms are positive regulators of human APOA5 gene transcription. Our data identify APOA5 as a new target gene for ROR and suggest a role for ROR in plasma triglyceride homeostasis.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Cloning and Construction of Recombinant Plasmids
The human APOA5 promoter fragment (–305/+62) was amplified by polymerase chain reaction (PCR) using an APOA5 genomic BAC clone^5,10 as template and cloned in the pGL3 luciferase vector. The forward oligonucleotide 5'-TCTGTTGGGGCCAGCCAG-3' and reverse oligonucleotide 5'-AATGCCCTCCCTTAGGACTGTGAC-3' primers were used for the PCR reaction. Site-directed mutagenesis of the construct (–305/+62) (–270^GC, –263^GA) was accomplished using the QuikChange site-directed mutagenesis kit (Stratagene) according to the recommendations of the manufacturer with the following oligonucleotides: forward 5'-AGTGGGAAGCTTAAAGATCATGGGGTT-3' and reverse 5'-AACCCCATGATCTTTAAGCTTCCCACT-3'. The human wild-type APOA5-DR1 (–284/-243) (5'-AGGTCAGTGGGAAGGTTAAAGGTCATGGGGTTTGGGAGAAAC-3') oligonucleotide was cloned in 4 copies into the SV40-pGL3. The pCDNA3-hROR expression vectors have been previously described.²⁶ The constructs Ad-GFP and Ad-ROR1, as well as the corresponding adenoviral particles, were prepared as described previously.²⁶ pAd-ROR4 and pAd-LacZ adenovirus were obtained by the Vira Power Adenoviral Expression system (Invitrogen, Paislay, UK). Briefly, ROR4 and control LacZ cDNA were cloned in pAd DEST-based expression vector (Bett et al, 1994); 293 A cells were transfected with pAd vectors to produce an adenoviral stock. This stock was amplified, purified on cesium chloride, and titered by a plaque assay in 96-well plates to define the titer in pfu/mL.

Cell Culture, Viral Infection, and Transient Transfection Assays
Human hepatoma HepG2 and HuH7 cells were obtained from the European Collection of Animal Cell Culture (Porton Down, Salisbury, UK). Cell lines were maintained in standard culture conditions (Dulbecco’s modified Eagle’s minimal essential medium) supplemented with 10% fetal calf serum, 5% nonessential amino acids, and 5% sodium pyruvate (Invitrogen) at 37°C CO₂, 95% air. Medium was changed every 2 days.

For adenovirus experiments, HepG2 cells were seeded in 6-well plates at a density of 5x10⁵ cells/well and incubated at 37°C before viral infection. Viral particles were added at a multiplicity of infection of 100 and incubated for 3 hours. HepG2 cells were infected with adenovirus coding, respectively, for ROR1 or ROR4 (Ad-ROR1, Ad-ROR4) or with control adenovirus coding for GFP (Ad-GFP, green fluorescent protein) or LacZ (Ad-LacZ, ß-galactosidase). Thereafter, cells were washed with phosphate-buffered saline and incubated in culture medium for the indicated times. At the end of the experiment, cells were washed once with ice-cold phosphate-buffered saline, lysed, and scraped in 0.5 mL of ice-cold Trizol reagent.

For transfection experiments, HepG2 and HuH7 cells were seeded in 24-well plates at a density of 10⁵ cells per well and incubated at 37°C for 16 hours before transfection. Cells were transfected by the calcium phosphate coprecipitation procedure using 300 ng of reporter vector and different quantities (10, 30, 100, and 300 ng) of pCDNA3-hROR1, 2, 3, 4, and expression vectors, or empty pCDNA3 plasmid vector as control. The total amount of DNA was kept constant by complementation with pCDNA3 empty vector. At the end of the experiment, the cells were washed with ice-cold phosphate-buffered saline, and the luciferase activity was measured using a luciferase assay system (Promega Corp, Madison, Wis).

Mice
Staggerer mutant mice were obtained by crossing heterozygote (+/sg) mice maintained in a C57BL/6 genetic background and maintained on chow diet as previously described.²⁴ Wild-type littermates of the same age as the homozygous mutants were used as control.

Gel Retardation Assays
The pCDNA3-hROR1, 2, 3, 4, and expression plasmids were transcribed in vitro using T7 polymerase and subsequently translated using rabbit reticulocyte lysate as recommended by the manufacturer (Promega). DNA protein-binding assays were conducted as described²⁷ using the following binding buffer: Hepes 10 mmol/L, KCl 60 mmol/L, glycerol 10%, MgCl₂ 5 mmol/L, EDTA 0.5 mmol/L, dithiothreitol 1 mmol/L, PMSF 1 mmol/L, poly(dIdC) 0.1 µg/µL, and herring sperm DNA 50 ng/µL containing 3 µL of programmed or unprogrammed reticulocyte lysate. Double-stranded oligonucleotides corresponding to the wild-type (forward 5'-GGGAAGGTTAAAGGTCATGGG-3' and reverse 5'-CCCATGACCTTTAACCTTCCC-3') or mutated (forward 5'-AGTGGGAAGCTTAAAGATCATGGGGTT-3' and reverse 5'-AACCCCATGATCTTTAAGCTTCCCACT-3') hAPOA5-DR1 response element present in the hAPOA5 promoter and oligonucleotides corresponding to the wild-type mapoa5 sequence (forward 5'-GGGGCGGTTGCTGGTCACAGGA-3' and reverse 5'-TCCTGTGACCAGCAACCGCCCC-3') were radiolabeled [-32P]ATP using T4 polynucleotide kinase and used as probes. For competition experiments, 25-, 100-, 200-, and 400-fold excess of cold wild-type or mutated probe was included 20 minutes before adding labeled probe. For supershift assays, 5 µL of 1X polyclonal ROR antibody (Santa Cruz Biotechnology, Le Perray en Yvelines, France) were added to the binding reaction. DNA-binding complexes were resolved by 5% native polyacrylamide gel electrophoresis (PAGE) in 0.25X TBE. Gels were dried and exposed at –80°C to XOMAT-AR film (Eastman Kodak Co, Rochester, New York).

RNA Analysis Experiments
Total RNA extraction was performed with Trizol reagent (Invitrogen) as indicated by the manufacturer. RNA expression of human and mouse apolipoprotein A5 and 36B4 genes was analyzed by real-time quantitative PCR using SYBR Green technology on a MX4000 apparatus (Stratagene Europe, Amsterdam, the Nederlands). PCR was performed with oligonucleotides forward 5'-ACGCACGCATCCAGCAGAAC-3' and reverse 5'-TCGGAGAGCATCTGGGGGTC-3' for human APOA5, forward 5'-CTCTGTCCCACAAACTCACACG 3' and reverse 5'-AGGTAGGTGTCATGCCGAAAAG-3' for mouse apoa5, and forward 5'-CATGCTCAACATCTCCCCCTTCTCC-3' and reverse 5'-GGGAAGGTGTAATCCGTCTCCACAG-3' for 36B4. Quantification of APOA5 and apoa5 mRNA levels was normalized using 36B4 as housekeeping gene.

Statistical Analysis
Results are presented as mean ± SD. Statistical analysis was performed using t tests and P<0.05 was considered statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
ROR1 and ROR4 Proteins Specifically Bind to a DR1 Site in the Human APOA5 Gene Promoter
It was previously described that peroxisome proliferator-activated receptor-/retinoid X receptor dimers bind to a DR1 site present at the position –272/–260 in the human APOA5 gene promoter.^10,11 Because this site presents structural homologies with the binding site for the orphan nuclear receptor hROR, we evaluated whether hROR proteins translated in vitro could bind to this site by electromobility shift assay. As shown in Figure 1A, only in vitro translated hROR1 and ROR4 proteins bound to the DR1 site, whereas ROR2, 3, and failed to bind this site (a SDS-PAGE analysis was performed with the translated products in the presence of 35S methionine and demonstrated that all the ROR isoforms, 1,2, 3, 4, and , are synthesized in equivalent amounts [data not shown]). The specificity of both hROR1 and ROR4 protein bindings to the hAPOA5 promoter ROR response element-direct repeat 1 (RORE-DR1), was determined first by using a specific antibody against ROR, which results in a supershift of the binding for ROR1 and in an inhibition of the binding for ROR4 (Figure 1A). Next, the mutated (–270^GC, –263^GA) radiolabeled DR1 site probe in electromobility shift assay failed to bind both ROR1 and ROR4 (Figure 1A). Furthermore, a competition with unlabeled wild-type RORE-DR1 site resulted in a complete inhibition of the binding. However, the unlabeled mutated RORE-DR1 (Figure 1B) failed to compete with the binding of both ROR1 and ROR4 proteins to the RORE-DR1 site. These data indicate that the RORE-DR1 site present in the human APOA5 gene promoter is a binding site for both ROR1 and ROR4 nuclear receptors.

View larger version (75K): [in this window] [in a new window]   Figure 1. ROR1 and ROR4 proteins bind specifically to the DR1 located at the position (–272/–260) of the human APOA5 gene promoter. Gel retardation assays were performed with the indicated end-labeled wild-type (wt) (–276/–256) (A and B) and mutant (mt) (–279/–253) (B) fragment of the human APOA5 gene promoter in the presence of in vitro transcribed/translated human ROR1 and 4 (A and B), human ROR2, 3, and ROR (A), or unprogrammed reticulocyte lysate as control (3 µL of each). Supershift assays were performed using 5 µL of a 1X polyclonal ROR specific antibody (A). DNA–protein complexes were resolved by nondenaturing PAGE. Specific complexes not observed with unprogrammed lysate are indicated by arrows. Competition experiments (B) were performed in the presence (+) or absence (–) of unlabeled wt (competition wt, 25-, 100-, 200-, and 400-fold molar excess) or mt (competition mt, 25-, 100-, 200-, and 400-fold molar excess) oligonucleotides.

Using a labeled consensus probe that binds in vitro monomers and dimers as reference, we determined that ROR1 and ROR4 bind as monomers to hAPOA5 RORE-DR1 (data not shown). Interestingly, hROR1 and hROR4 proteins, which are the only isoforms expressed in the liver,²⁸ can bind to the identified RORE, whereas hROR2, hROR3, and hROR proteins cannot bind to this response element (Figure 1A).

To determine whether this binding could be extended to mice, the mouse homologous region was tested in an electromobility shift assay with in vitro translated ROR proteins. No binding was observed with the mouse site (Figure 2A). In addition, the comparison of the identified human APOA5 RORE-DR1 with the homologous region of other species showed that this site is conserved only in chimpanzee and baboon sequences (Figure 2B). In mouse, the homologous site deviates from the core motif by 1 nucleotide, and this divergence could explain the lack of binding in gel shift assay.

View larger version (55K): [in this window] [in a new window]   Figure 2. ROR proteins do not bind to the mouse promoter homologous sequence. A, A gel retardation assay was performed with the wild-type fragment of the mouse APOA5 gene promoter homologous to the human RORE-DR1 in the presence of in vitro transcribed/translated ROR1, ROR2, ROR3, ROR4, and ROR or unprogrammed reticulocyte lysate as control (3 µL of each). DNA–protein complexes were resolved by nondenaturing PAGE. No specific complex was observed. B, The human and the other species promoter sequences homologous to the human RORE-DR1 were aligned. The sequence corresponding to the human PPRE-DR1 site AGGTTAAAGGTCA is in bold and the sequence corresponding to the human RORE half-core motif AGGTCA is underlined.

ROR1 and ROR4 Enhance the Activity of the Human APOA5 Gene Promoter
Next, we investigated whether ROR1, 2, 3, 4, and can modulate APOA5 gene promoter transcriptional activity. HepG2 and HuH7 human hepatocytes were transiently cotransfected with a luciferase reporter vector driven by the human promoter fragment (–305/+62) (Figure 3A) and the different isoforms of ROR. The results in Figure 3B (HepG2 cells) and 3C (HuH7 cells) show that only ROR1 and ROR4 increased human APOA5 promoter activity, whereas ROR2, 3, and had no effect. These data are in agreement with the gel shift assay findings and confirm that only ROR1 and ROR4 are functional. Then, we showed that the transcriptional activity of the APOA5 reporter construct was strongly increased in a dose-dependent manner by the cotransfection of either ROR1 or ROR4 expression vectors in HepG2 cells (Figure 3D) and in HuH7 cells (Figure 3E). To demonstrate that the increase of human promoter activity by ROR1 and ROR4 is caused by their binding to the identified RORE-DR1 at the position –272/–260, HepG2 and HuH7 cells were transiently transfected with the luciferase reporter vector driven by the mutated human APOA5 promoter fragment –305/+62 (–270^GC, –263^GA). The response of the mutated construct to ROR1 or ROR4 was strongly decreased compared with the wild-type construct in HepG2 (Figure 4A) and in HuH7 cells (Figure 4B). These results suggest that the identified RORE-DR1 plays a key role in the regulation of the human APOA5 transcriptional activity by ROR. However, because 18% residual increase is still observed with the mutated construct, we cannot exclude that another mechanism independent of the binding to this site could exist. To further demonstrate that the APOA5 RORE-DR1 is functional, we cloned it in 4 tandem copies in front of an heterologous promoter and examined its response to ROR1 or ROR4 cotransfection in HepG2 and HuH7 cells. We found that this site is able to transmit ROR1 and ROR4 activator effect in a dose-dependent manner in HepG2 (Figure 4C) and in HuH7 cells (Figure 4D). Taken together, these results demonstrate that ROR1 and ROR4 increase APOA5 promoter transcriptional activity mainly by a specific binding to the RORE-DR1 at position –272/–260.

View larger version (27K): [in this window] [in a new window]   Figure 3. ROR1 and ROR4 enhance the activity of the human APOA5 gene promoter in a dose-dependent manner. A, The APOA5 promoter (–305/+62) was used for the transient transfections. Exon 1 is depicted by a box with the start site of transcription indicated by +1. The RORE-DR1 site (–272/–260) is in bold and the 2 mutated nucleotides are underlined. HepG2 (B) and HuH7 (C) cells were transiently cotransfected with the wild-type human APOA5 promoter fragment reporter plasmid (–305/+62) cloned in front of the luciferase reporter gene (300 ng) and the pCDNA3-hROR1, 2, 3, 4, and expression plasmids (30 and 100 ng) or the empty pCDNA3 vector. HepG2 (D) and HuH7 (E) cells were transiently cotransfected with the wild-type human APOA5 promoter fragment reporter plasmid (–305/+62) cloned in front of the luciferase reporter gene (300 ng) and the pCDNA3-hROR1 and pCDNA3-hROR4 expression plasmids (10, 30, 100, and 300 ng), or the empty pCDNA3 vector as control (300 ng) for 24 hours. Statistical differences from controls are indicated by asterisks (**P<0.01 and ***P<0.001).

View larger version (21K): [in this window] [in a new window]   Figure 4. The (–305/+62) region of the human APOA5 gene promoter is activated by ROR1 and ROR4 mainly via the functional RORE-DR1 present at the position (–272/–260). HepG2 (A) and HuH7 (B) cells were transiently cotransfected with the mutated APOA5 promoter fragment reporter plasmid –305/+62 (–270GC, –263GA) cloned in front of the luciferase reporter gene (300 ng) and the expression plasmids pCDNA3-hROR1, pCDNA3-hROR4 (100 and 300 ng), or the empty pCDNA3 vector as control (300 ng) for 24 hours. HepG2 (C) and HuH7 (D) cells were transiently cotransfected with the reporter construct containing four tandem copies of the human APOA5 RORE-DR1 inserted in front of an heterologous promoter cloned upstream of the luciferase reporter gene (300 ng) and the pCDNA3-hROR1 and pCDNA3-hROR4 expression plasmids (100 and 300 ng), or the empty pCDNA3 vector as control (300 ng) for 24 hours. Statistical differences from controls are indicated by asterisks (*P<0.05; **P<0.01 and ***P<0.001).

Furthermore, we determined that none of the ROR isoforms had any effect on the mouse promoter activity (data not shown). This is in agreement with the absence of binding in gel shift assay.

The Adenovirus-Mediated Overexpression of hROR1 and hROR4 Lead to Increase hAPOA5 mRNA Accumulation
To evaluate whether the overexpression of hROR1 and hROR4 could lead to an increase of hAPOA5 mRNA levels, HepG2 cells were infected with the Ad-ROR1 or the Ad-ROR4 adenoviral expression vector. As control, HepG2 cells were infected with the same vector, allowing expression of GFP or LacZ. Total RNA was extracted and analyzed by real-time quantitative PCR using hAPOA5-specific oligonucleotides and 36B4 as an internal control. As shown in Figure 5A, an increase of hAPOA5 mRNA was observed in cells infected with the hROR1 adenoviral expression vector compared with control cells infected with Ad-GFP. In addition, the adenovirus-induced hAPOA5 mRNA accumulation was shown to be time-dependent to reach a 6-fold increase after 48-hour incubation. A significant increase of hAPOA5 mRNA was also observed in HepG2 cells infected with Ad-ROR4 compared with their control cells infected with Ad-LacZ (Figure 5B). These results confirm that hROR1 and hROR4 play a key role in the physiological control of APOA5 gene expression in human HepG2 cells.

View larger version (27K): [in this window] [in a new window]   Figure 5. A and B, Adenovirus-mediated overexpression of hROR1 or hROR4 leads to increase hAPOA5 mRNA accumulation in HepG2 cells. Human HepG2 cells seeded at a density of 5x105 cells/dish were infected for 3 hours. As indicated, cells were infected with adenovirus expressing respectively ROR1 and ROR4 [Ad-ROR1 (A) or the Ad-ROR4 (B)] or with control adenovirus expressing GFP (Ad-GFP) or LacZ (Ad-LacZ) at a multiplicity of infection of 100. Then, cells were washed and incubated for the indicated time in standard culture medium. At the end of the experiment, cells were washed and lysed in Trizol reagent. Total mRNA was extracted and analyzed by quantitative RT-PCR on a Mx4000 apparatus (Stratagene). Results are expressed as percent of control. C, There is no significant difference between staggerer mice and wild-type littermates mapoa5 mRNA levels. Homozygous staggerer mice (3 mice) and their wild-type littermates (5 mice) generated in an inbred C57BL/6 genetic background were euthanized. Liver RNA expression of mapoa5 and 36B4 genes were analyzed by reverse-transcription PCR. Results are expressed as percent of control. Statistical differences from controls are indicated by asterisks (**P<0.01 and ***P<0.001).

Furthermore, we analyzed the hepatic apoa5 gene expression in staggerer mice, which carry a natural deletion in the ROR gene (Figure 5C). No effect has been observed indicating that mouse apoa5 is not affected by ROR.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
It is well-established that hypertriglyceridemia constitutes an independent risk factor for cardiovascular diseases.^3,4 Because APOA5 has been described as a crucial determinant of plasma triglyceride levels,⁵ the identification of factors that regulate its expression is of major medical importance for the treatment of hypertriglyceridemia and associated coronary heart disease. It has been reported that hAPOA5 gene expression is upregulated by the heterodimer peroxisome proliferator-activated receptor-/retinoid X receptor by a direct binding to the direct repeat 1.^10,11 Because this DR1 site presents structural homologies with the binding site for the orphan nuclear receptor ROR, we investigated the role of ROR in the control of hAPOA5 gene expression. Several studies attributed an important role to ROR in the regulation of lipid homeostasis by upregulating some apolipoprotein gene expression as APOA1 and APOC3 at the transcriptional level^23,24 and recently caveolin-3 and CPT-I in skeletal muscle.²⁹ Moreover, it has been shown that ROR has been shown to play a role in lipid homeostasis in the vascular wall.³⁰ Besnard et al demonstrated that ROR expression is significantly decreased in human atherosclerotic plaques.³⁰ In addition, sg/sg mice have an increased susceptibility to atherosclerosis²⁵ attributed to lower high-density lipoprotein plasma levels and to heightened inflammatory response.²⁶

We demonstrated initially that both ROR1 and ROR4 can specifically bind to the identified RORE site –272/–260 present in the human APOA5 gene promoter, which consists of a perfect AGGTCA half-site core motif. The functional evaluation of this site, using transient cotransfection experiments with ROR and wild-type or mutated RORE in the context of the hAPOA5 promoter, demonstrated that only ROR1 and ROR4 increase human APOA5 promoter activity in HepG2, as well as in HuH7 cells. In addition, in vitro experiments with Ad-ROR adenoviral expression vectors revealed that ROR1 and ROR4 overexpression lead to APOA5 mRNA accumulation in HepG2 cells. Our data demonstrate that human APOA5 is a new target gene for ROR1 and ROR4. These data could strengthen the role of ROR in lipid homeostasis.

The second objective of our study was to evaluate whether our results obtained in human could be extended to mouse. The sg/sg mice, which carry a natural mutation in the ROR gene, exhibit an aberrant blood lipid profile associated with changes in plasma apolipoprotein levels. In particular, sg/sg mice display decreased apoC-III and triglyceride plasma levels.²⁵ Because the triglyceride metabolism was affected in this mouse model, we addressed the question whether apoa5 gene is involved in this mechanism. However, we show that the apoa5 gene expression is not altered in the sg/sg mice. In addition, EMSA and transient transfection experiments (data not shown) results suggested that the homologous site of human APOA5 RORE-DR1, identified at the position –272/–260, is not functional in mice. The alignment of the human and mouse promoter sequences revealed that the mouse deviates from the human APOA5 RORE-DR1 core by 1 nucleotide and this could probably explain the nonfunctionality of this site. These data indicated that ROR cannot modulate apoa5 gene expression in mice and that APOA5 is a ROR target gene only in humans.

In a recent study, it was demonstrated that apoA-V and apoC-III independently influence plasma triglyceride concentrations in an opposite manner.³¹ It is well-known that apoC-III, which is a component of VLDL, increases triglyceride levels via an inhibitory effect on lipoprotein lipase activity and thus constitutes a risk factor for atherosclerosis.³² The apoC-III has been reported to be upregulated by ROR and these data rather argue against the potential protective effect of ROR in atherosclerosis. Interestingly, in our study, we demonstrate that ROR strongly increases hAPOA5 gene expression in human hepatocytes. This new finding confers to ROR a beneficial role in the regulation of triglyceride metabolism that could counteract apoC-III effect. By regulating the gene expression of both apolipoproteins, ROR may play a determinant role, at least in maintaining plasma triglyceride levels in humans. In mice, a different approach may be expected because apoc3 is increased, whereas apoa5 seems to be unaffected. This hypothesis correlates with the lower circulating plasma triglyceride levels observed in sg/sg mice, which could be caused by the repression of apoc3 by the deleted ROR but not by the downregulation of apoa5 in this animal model.

In conclusion, we speculate that the upregulation of hAPOA5 expression might counteract the negative effect of the upregulation of APOC3 by ROR in humans and could avoid the elevation of plasma triglyceride levels. These new findings make ROR a more attractive therapeutic target in the treatment of dyslipidemia and atherosclerosis.

	Acknowledgments

 
This work was supported by the Leducq Foundation.

Received September 20, 2004; accepted March 9, 2005.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998; 81: 13B–17B.[CrossRef][Medline] [Order article via Infotrieve]

2. Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation. 1999; 99: 2852–2854.[Free Full Text]

3. Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation. 1999; 100: 475–482.[Abstract/Free Full Text]

4. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000; 86: 943–949.[CrossRef][Medline] [Order article via Infotrieve]

5. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294: 169–173.[Abstract/Free Full Text]

6. van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, Chamuleau RA. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem. 2001; 276: 44512–44520.[Abstract/Free Full Text]

7. Fruchart-Najib J, Bauge E, Niculescu LS, Pham T, Thomas B, Rommens C, Majd Z, Brewer B, Pennacchio LA, Fruchart JC. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun. 2004; 319: 397–404.[CrossRef][Medline] [Order article via Infotrieve]

8. Talmud PJ, Martin S, Taskinen MR, Frick MH, Nieminen MS, Kesaniemi YA, Pasternack A, Humphries SE, Syvanne M. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res. 2004; 45: 750–756.[Abstract/Free Full Text]

9. Hubacek JA, Skodova Z, Adamkova V, Lanska V, Poledne R. The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin Genet. 2004; 65: 126–130.[CrossRef][Medline] [Order article via Infotrieve]

10. Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, Fruchart JC. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem. 2003; 278: 17982–17985.[Abstract/Free Full Text]

11. Prieur X, Coste H, Rodriguez JC. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem. 2003; 278: 25468–25480.[Abstract/Free Full Text]

12. Jakel H, Nowak M, Moitrot E, Dehondt H, Hum DW, Pennacchio LA, Fruchart-Najib J, Fruchart JC. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem. 2004; 279: 45462–45469.[Abstract/Free Full Text]

13. Hirose T, Smith RJ, Jetten AM. ROR gamma: the third member of ROR/RZR orphan receptor subfamily that is highly expressed in skeletal muscle. Biochem Biophys Res Commun. 1994; 205: 1976–1983.[CrossRef][Medline] [Order article via Infotrieve]

14. Carlberg C, Hooft van Huijsduijnen R, Staple JK, DeLamarter JF, Becker-Andre M. RZRs, a new family of retinoid-related orphan receptors that function as both monomers and homodimers. Mol Endocrinol. 1994; 8: 757–770.[Abstract/Free Full Text]

15. Giguere V, Tini M, Flock G, Ong E, Evans RM, Otulakowski G. Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors. Genes Dev. 1994; 8: 538–553.[Abstract/Free Full Text]

16. Forman BM, Chen J, Blumberg B, Kliewer SA, Henshaw R, Ong ES, Evans RM. Cross-talk among ROR alpha 1 and the Rev-erb family of orphan nuclear receptors. Mol Endocrinol. 1994; 8: 1253–1261.[Abstract/Free Full Text]

17. Giguere V, McBroom LD, Flock G. Determinants of target gene specificity for ROR alpha 1: monomeric DNA binding by an orphan nuclear receptor. Mol Cell Biol. 1995; 15: 2517–2526.[Abstract]

18. Harding HP, Atkins GB, Jaffe AB, Seo WJ, Lazar MA. Transcriptional activation and repression by RORalpha, an orphan nuclear receptor required for cerebellar development. Mol Endocrinol. 1997; 11: 1737–1746.[Abstract/Free Full Text]

19. Becker-Andre M, Andre E, DeLamarter JF. Identification of nuclear receptor mRNAs by RT-PCR amplification of conserved zinc-finger motif sequences. Biochem Biophys Res Commun. 1993; 194: 1371–1379.[CrossRef][Medline] [Order article via Infotrieve]

20. Schaeren-Wiemers N, Andre E, Kapfhammer JP, Becker-Andre M. The expression pattern of the orphan nuclear receptor RORbeta in the developing and adult rat nervous system suggests a role in the processing of sensory information and in circadian rhythm. Eur J Neurosci. 1997; 9: 2687–2701.[CrossRef][Medline] [Order article via Infotrieve]

21. Hamilton BA, Frankel WN, Kerrebrock AW, Hawkins TL, FitzHugh W, Kusumi K, Russell LB, Mueller KL, van Berkel V, Birren BW, Kruglyak L, Lander ES. Disruption of the nuclear hormone receptor RORalpha in staggerer mice. Nature. 1996; 379: 736–739.[CrossRef][Medline] [Order article via Infotrieve]

22. Sidman RL, Lane PW, Dickie MM. Staggerer, a new mutation in the mouse affecting the cerebellum. Science. 1962; 137: 610–612.[Abstract/Free Full Text]

23. Vu-Dac N, Gervois P, Grotzinger T, De Vos P, Schoonjans K, Fruchart JC, Auwerx J, Mariani J, Tedgui A, Staels B. Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORalpha. J Biol Chem. 1997; 272: 22401–22404.[Abstract/Free Full Text]

24. Raspe E, Duez H, Gervois P, Fievet C, Fruchart JC, Besnard S, Mariani J, Tedgui A, Staels B. Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. J Biol Chem. 2001; 276: 2865–2871.[Abstract/Free Full Text]

25. Mamontova A, Seguret-Mace S, Esposito B, Chaniale C, Bouly M, Delhaye-Bouchaud N, Luc G, Staels B, Duverger N, Mariani J, Tedgui A. Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalpha. Circulation. 1998; 98: 2738–2743.[Abstract/Free Full Text]

26. Delerive P, Monte D, Dubois G, Trottein F, Fruchart-Najib J, Mariani J, Fruchart JC, Staels B. The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. EMBO Rep. 2001; 2: 42–48.[CrossRef][Medline] [Order article via Infotrieve]

27. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994; 269: 31012–31018.[Abstract/Free Full Text]

28. Chauvet C, Bois-Joyeux B, Danan JL. Retinoic acid receptor-related orphan receptor (ROR) alpha4 is the predominant isoform of the nuclear receptor RORalpha in the liver and is up-regulated by hypoxia in HepG2 human hepatoma cells. Biochem J. 2002; 364: 449–456.[CrossRef][Medline] [Order article via Infotrieve]

29. Lau P, Nixon SJ, Parton RG, Muscat GE. RORalpha regulates the expression of genes involved in lipid homeostasis in skeletal muscle cells: caveolin-3 and CPT-1 are direct targets of ROR. J Biol Chem. 2004; 279: 36828–36840.[Abstract/Free Full Text]

30. Besnard S, Heymes C, Merval R, Rodriguez M, Galizzi JP, Boutin JA, Mariani J, Tedgui A. Expression and regulation of the nuclear receptor RORalpha in human vascular cells. FEBS Lett. 2002; 511: 36–40.[CrossRef][Medline] [Order article via Infotrieve]

31. Baroukh N, Bauge E, Akiyama J, Chang J, Afzal V, Fruchart JC, Rubin EM, Fruchart-Najib J, Pennacchio LA. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol. 2004; 24: 1297–1302.[Abstract/Free Full Text]

32. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res. 2003; 44: 2374–2381.[Abstract/Free Full Text]

Related Article:

ApoA-V: The Regulation of a Regulator of Plasma Triglycerides

Sven-Olof Olofsson
Arterioscler Thromb Vasc Biol 2005 25: 1097-1099. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				Y. Chen, S. Coulter, A. M. Jetten, and J. A. Goldstein Identification of Human CYP2C8 as a Retinoid-Related Orphan Nuclear Receptor Target Gene J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 192 - 201. [Abstract] [Full Text] [PDF]

				Y.-J. Li, Y.-S. Wei, X.-H. Fu, D.-L. Hao, Z. Xue, H. Gong, Z.-Q. Zhang, D.-P. Liu, and C.-C. Liang The Apolipoprotein CIII Enhancer Regulates Both Extensive Histone Modification and Intergenic Transcription of Human Apolipoprotien AI/CIII/AIV Genes but Not Apolipoprotein AV J. Biol. Chem., October 17, 2008; 283(42): 28436 - 28444. [Abstract] [Full Text] [PDF]

				G. Benoit, A. Cooney, V. Giguere, H. Ingraham, M. Lazar, G. Muscat, T. Perlmann, J.-P. Renaud, J. Schwabe, F. Sladek, et al. International Union of Pharmacology. LXVI. Orphan Nuclear Receptors Pharmacol. Rev., December 1, 2006; 58(4): 798 - 836. [Abstract] [Full Text] [PDF]

				J. Wang, L. Yin, and M. A. Lazar The Orphan Nuclear Receptor Rev-erb{alpha} Regulates Circadian Expression of Plasminogen Activator Inhibitor Type 1 J. Biol. Chem., November 10, 2006; 281(45): 33842 - 33848. [Abstract] [Full Text] [PDF]

				D. C. Chan, G. F. Watts, M. N. Nguyen, and P. H. R. Barrett Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 590 - 596. [Abstract] [Full Text] [PDF]

				E. A. Ruiz-Narvaez, Y. Yang, Y. Nakanishi, J. Kirchdorfer, and H. Campos APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica J. Lipid Res., December 1, 2005; 46(12): 2605 - 2613. [Abstract] [Full Text] [PDF]

				S.-O. Olofsson ApoA-V: The Regulation of a Regulator of Plasma Triglycerides Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1097 - 1099. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 25/6/1186    most recent 01.ATV.0000163841.85333.83v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Genoux, A. Articles by Fruchart, J.-C. Search for Related Content PubMed PubMed Citation Articles by Genoux, A. Articles by Fruchart, J.-C. Related Collections Related Article